US Patent

US11879013 — Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors

Method of Use · Assigned to Janssen Biotech Inc · Expires 2040-05-21 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects combination therapies using bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors.

USPTO Abstract

The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3 rd generation EGFR tyrosine kinase inhibitors.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3985 — lazertinib-mesylate
U-3985 — lazertinib-mesylate

Patent Metadata

Patent number
US11879013
Jurisdiction
US
Classification
Method of Use
Expires
2040-05-21
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Biotech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.